 |
|
|
 |
.TOP NEWS
Read a Special-Edition Case Spotlight
This Case Spotlight is supported by Genentech. All content is the property of, and has been developed by, SIO, and includes opinions of the participating physicians.
The Society of Interventional Oncology is pleased to share key findings from interesting patient cases within the IO community through our Case Spotlight content offerings.
Read the latest Case Spotlight now, which features a conversation between:
|
|
Register for SIO2023 Before Rates Increase!
The SIO2023 Annual Scientific Meeting is taking place 19–23 January 2023 in Washington, D.C., USA. Save the Date for our long list of learning opportunities and networking events! Get a chance to meet face-to-face at all our networking functions this year, and even test your knowledge at our event "SIO Presents: DC After Dark."
View the conference program today!
Don't delay — register today! Registration rates increase beginning on 1 January 2023.
Please email info@sio-central.org with any questions regarding SIO2023 registration.
|
|
.INDUSTRY NEWS
What's the most cost-effective way to diagnose liver metastases?
Aunt Minnie
MRI appears to be the most cost-effective modality for diagnosing colorectal cancer liver metastases, a presenter said in a November 27 session at RSNA 2022. The findings could not only help clinicians determine how best to image patients with suspected colorectal cancer metastases from a cost perspective but also benefit patients — since one of MRI's strengths is that it doesn't impart radiation.
|
|
|
|
 |
|
Outcomes in the first 100 patients treated with the OsteoCool™ Radiofrequency Ablation System from the OPuS One trial were recently published in the November edition of the Journal of Vascular and Interventional Radiology (JVIR). Learn more about the largest prospective study in radiofrequency ablation for bone metastases.
|
|
Therapeutic effects of anti-PD1 immunotherapy on hepatocellular carcinoma under administration of tacrolimus
Transplantation
Liver transplantation (LT) is the treatment of choice for patients with hepatocellular carcinoma (HCC). Recurrence of HCC after LT occurs in 10% to 20% of cases. Preclinical studies to evaluate immune checkpoint inhibitors in conjunction with immunosuppressant treatment in transplant recipients have been lacking. Here, we evaluated the efficacy, safety, and mechanism of programmed cell death-1 (PD1) blockade under tacrolimus treatment in transplant recipients.
|
|
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063 |
